Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations

European Journal of Cardio-thoracic Surgery

Volumn 51, Issue 2, 2017, Pages 255-262

  Renaud, Stéphane ^a,b   Schaeffer, Mickaël ^a   Falcoz, Pierre Emmanuel ^a   Seitlinger, Joseph ^a   Romain, Benoit ^a,b   Voegeli, Anne Claire ^a   Legrain, Michèle ^a   Reeb, Jérémie ^a   Santelmo, Nicola ^a   Rohr, Serge ^a   Brigand, Cécile ^a   Olland, Anne ^a   Guenot, Dominique ^b   Massard, Gilbert ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Bevacizumab; BRAF; Colorectal cancer; KRAS; Lung; Metastasectomy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL OUTCOME; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; LUNG LOBECTOMY; LUNG METASTASIS; LUNG SEGMENTECTOMY; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MIDDLE AGED; ONCOGENE K RAS; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SEGMENTECTOMY; V RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; VIRUS ONCOGENE; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; DRUG ADMINISTRATION; FOLLOW UP; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MUTATION; NEOADJUVANT THERAPY; RETROSPECTIVE STUDY; SECONDARY; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES;

EID: 85016044743     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezw304     Document Type: Article

References (21)

1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF et al. The Global Burden of Cancer 2013. JAMA Oncol 2015;1:505-27.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
3. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 1984;3:303-24.
4. Engstrom PF, Arnoletti JP, Benson AB III, Chen YJ, Choti MA, Cooper HS et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw 2009;7:778-831.
5. Pfannschmidt J, Hoffmann H, Dienemann H. Reported outcome factors for pulmonary resection in metastatic colorectal cancer. J Thorac Oncol 2010;5:S172-8.
6. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26:5721-7.
7. Salah S, Watanabe K, Welter S, Park JS, Park JW, Zabaleta J et al. Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. Ann Oncol 2012;23:2649-55.
8. Gonzalez M, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: systematic review and meta-analysis. Future Oncol 2015;11:31-3.
9. Ghidini M, Personeni N, Bozzarelli S, Baretti M, Basso G, Bianchi P et al. KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Med 2016;5:256-64.
10. Renaud S, Romain B, Falcoz PE, Olland A, Santelmo N, Brigand C et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer 2015;112:720-8.
11. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16.
12. Park HS, Jung M, Shin SJ, Heo SJ, Kim CG, Lee MG et al. Benefit of adjuvant chemotherapy after curative resection of lung metastasis in colorectal cancer. Ann Surg Oncol 2016;23:928-35.
13. Hawkes EA, Ladas G, Cunningham D, Nicholson AG, Wassilew K, Barbachano Y et al. Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. BMC Cancer 2012;12:326.
14. Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG et al. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget 2014;5:6584-93.
15. McElnay P, Lim E. Adjuvant or neoadjuvant chemotherapy for NSCLC. J Thorac Dis 2014;6(Suppl. 2):S224-7.
16. Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A et al. KRAS exon 2 mutations as prognostic indicators in advanced colorectal cancer in clinical practice: a mono-institutional study. Mol Diagn Ther 2016;20:65-74.
17. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-39.
18. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000;60:6750-6.
19. Schweiger T, Nikolowsky C, Graeter T, Seebacher G, Laufer J, Glueck O et al. Increased lymphangiogenesis in lung metastases from colorectal cancer is associated with early lymph node recurrence and decreased overall survival. Clin Exp Metastasis 2016;33:133-41.
20. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.
21. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009;4:e8199.